DGAP-News: B.R.A.I.N. Biotechnology Research and Information Network AG

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN and Südzucker cooperate in the field of CO2 utilisation by microorganisms

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Alliance B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN and Südzucker cooperate in the field of CO2 utilisation by microorganisms

13.04.2016 / 10:01 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

BRAIN and Südzucker cooperate in the field of CO2 utilisation by microorganisms

Zwingenberg, April 13, 2016 - BRAIN AG (ISIN DE0005203947 / WKN 520394), one of Europe's bio-economy leaders, expands its cooperation with Südzucker AG in the field of microbial utilisation of carbon dioxide. The cooperation with the largest producer of sugar in the European Union is co-financed by the German Ministry of Education and Research (BMBF) as part of the strategic alliance ZeroCarbFP. It aims at making the industrial by-product CO2 available for the production of a multitude of economically interesting intermediates by using microorganisms.

Based on very promising laboratory results during Phase 1 of the alliance, the two partners have now applied for further funding with the BMBF in order to scale up the process to a pilot facility at Südzucker's CO2-emitting bioethanol plant in Zeitz during Phase 2. The goal is to transform the CO2 generated during the production of bioethanol into a material building block by using specific microorganisms, and ultimately to reduce CO2 emissions. The intermediate products generated from CO2, such as mono- and dicarboxylic acids, may then be utilised as specialty products in the bioplastics industry, which so far has been dependent on fossil resources.

"We are delighted to have reached the first milestones in our cooperation using CO2 as a valuable resource," says Dr Jürgen Eck, CEO of BRAIN AG. "In addition, we see the potential of using the technology, which we developed in cooperation with our partner, in other CO2-emitting processes as well, thus permitting us to make it available for wide-spread industrial use. The microorganisms are undemanding and can easily adapt to different sources of carbon dioxide."

In comparison to other processes, the two-stage process co-developed with Südzucker for the utilisation of CO2 from bioethanol plants allows for high carbon fixation rates as well as a variety of mono- and dicarboxylic acids for the production of biopolymers.

For additional information please refer to the joint press release of BRAIN AG and Südzucker AG at https://www.brain-biotech.de/en/press.

About BRAIN BRAIN AG is one of Europe's technology leaders in the field of industrial 'white' biotechnology. Within strategic alliances, BRAIN AG has identified and developed numerous innovative products and solutions for companies in the chemical, pharmaceutical, cosmetic and food industries by harnessing nature's untapped biodiversity. These active product components are identified by BRAIN AG and contained in the company's "BioArchive", one of the most comprehensive archives of its kind. Since its foundation in 1993, BRAIN has entered into 102 strategic cooperations with nearly every prominent company in the chemical industry. Cooperation partners include BASF, Bayer Schering, Clariant, DSM, Evonik Degussa, Henkel, Nutrinova, RWE, Sandoz, Südzucker and Symrise. The company currently employs around 120 highly skilled personnel. www.brain-biotech.de

Contact:

B.R.A.I.N Biotechnology Research And Information Network AG Dr. Martin Langer Executive Vice President Corporate Development Darmstädter Str. 34-36 64673 Zwingenberg, Germany

Tel.: +49-6251-9331-0 Fax: +49-6251-9331-11 E-Mail: ir@brain-biotech.de www.brain-biotech.de

Disclaimer

This publication does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for any securities. The public offer of shares of B.R.A.I.N. Biotechnology Research And Information Network AG is already concluded. This release is not for publication, release or distribution in the United States of America, Canada, Australia or Japan.

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

---------------------------------------------------------------------------

13.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: ir@brain-biotech.de Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service ---------------------------------------------------------------------------

453833 13.04.2016